Update on acquisition of securities of O2 Renewable Energy XXIV Private Limited

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Q2 FY 2025 Results – Newspaper Advertisement

Unaudited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine Months ended 31st December, 2025

Newspaper Advertisement

Newspaper Advertisement

AGM Date Intimation

Glenmark’s Q1 FY 2024 – 25 Results – Newspaper Advertisement

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

Glenmark’s Q4 FY 2023-24 Results – Newspaper Advertisement

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Investor Day intimation

Intimation of Acquisition

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

Credit Ratings -rating rationale issued by India Ratings and Research

Credit Ratings -rating rationale issued by India Ratings and Research

Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

Retirement of Independent Directors

Credit Ratings – rating research update issued by CRISIL Ratings

Disclosure pursuant to Regulation 30(7) of SEBI LODR

Credit Ratings -rating research update issued by S&P Global ratings

Disclosure pursuant to Regulation 30(7) of SEBI LODR

Intimation of Schedule of Analyst-Institutional investor meeting, February 2024

Glenmark’s Q3 FY 2023-24 Results – Newspaper Advertisement

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

Glenmark’s MDA Q3 FY 2023 – 24

Glenmark’s Q3 FY 2023-24 Results